NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced its participation in two major medical industry conferences: the American Epilepsy Society (AES) 2025 Annual Meeting and the CNS Drug Delivery Summit. The AES meeting will take place from December 5 to December 9 in Atlanta, GA, while the CNS Drug Delivery Summit is scheduled for December 9 to December 11 in Boston, MA. These events provide a platform for NeuroOne to engage with healthcare professionals and industry experts focused on advancing treatments for neurological conditions.
The AES Annual Meeting, accessible via registration, gathers epileptologists, neurosurgeons, researchers, and advocates dedicated to improving outcomes for epilepsy patients. NeuroOne's participation underscores its commitment to developing minimally invasive solutions for EEG recording, monitoring, ablation, and stimulation. The company's technology aims to enhance surgical precision and reduce procedural costs for epilepsy and other neurological disorders.
The CNS Drug Delivery Summit, detailed on the conference website, brings together over 100 experts including neuroscientists, chemists, and device engineers. This summit focuses on overcoming challenges in delivering therapeutics to the brain. NeuroOne's involvement highlights its expertise in drug delivery solutions, which complement its existing portfolio of neuromodulation devices. The company is exploring applications in Parkinson's disease, essential tremors, chronic pain, and other conditions.
NeuroOne's presence at these conferences aligns with its mission to improve surgical care for neurological disorders. The company's advanced electrode technology offers high-definition EEG recording and targeted stimulation capabilities. By engaging with the scientific community at AES and the CNS Drug Delivery Summit, NeuroOne aims to foster collaborations and accelerate the adoption of its technologies. The conferences also serve as a venue to discuss potential future applications in depression, mood disorders, and artificial intelligence.
For more information about NeuroOne and its product pipeline, visit the company's website at nmtc1.com. The company continues to seek opportunities to expand its impact on neurological care through innovation and strategic partnerships.
